Genkyotex - Ready to make a dent in the fibrosis market
Genkyotex has initiated a Phase II investigator-sponsored trial in patients with Type 1 diabetes (T1D) and kidney disease (DKD). Separately, it has announced the positive outcome of a safety review of its Phase II trial with GKT831 in patients with primary biliary cholangitis (PBC) with no adverse events or patient dropouts. Interim data have been pushed back slightly to autumn 2018 from mid-2018 and full data to H119 from end-2018 due to a slow rate of activation of a number of research centres. Additionally, the original deal with the Serum Institute of India Ltd (SIIL) has been expanded and Genkyotex is now eligible to an additional €100m in milestone payments plus royalties on sales. We include the DKD indication and the new terms with SIIL in our valuation, which is now €338.7m or €4.35/share.Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.